More than 200 guests joined us on Thursday 16 September for a spectacular evening under the dome at Snowball 2025.
We are pleased to provide an update on a pioneering research project to develop a new cellular immunotherapy for T-cell lymphoma.
Clinical trials make hope real for Australian blood cancer patients by transforming cutting-edge scientific findings into tangible treatment options.
The Snowdome Foundation is inviting applications for the 2025 Cannon Family Travel Grants.
Snowdome is delighted to announce the 2025 Klempfner Snowdome Fellowship, led by Prof. Mark Dawson at the Peter MacCallum Cancer Centre.
A global Phase 1 clinical trial is actively recruiting new patients to further investigate the potential benefits of this innovative treatment which uses healthy donor cells to recognise and attack blood cancer cells.
Snowdome Foundation is incredibly fortunate to have the support of a Board of Directors and various committees that are made up entirely of volunteers.
We are delighted to share that eltranatamab, an immunotherapy drug, specifically known as a bispecific antibody will be made available later in 2025 for Australian myeloma patients.
2024 Cannon Family Travel Grant recipient, Dr Edward Cliff, a third-year clinical haematology registrar at the Peter MacCallum Cancer Centre and Royal Melbourne Hospital, recently attended the American Society of Haematology (ASH) Annual Meeting in California.